Celltrion Pharm셀트리온제약

Celltrion Pharm068760· Biotech & PharmaInitiation

Celltrion Pharm: Steady Profit Growth, Shares Down 28.8% Over a Year, Model Estimate Below Price

Celltrion Pharm's trailing revenue reached ₩578.0B with an operating margin of 10.7% as of H1 2026, while the share price closed at ₩38,300, down 28.8% over one year. The valuation model's base estimate of ₩21,706 per share sits below the current price, and several data points such as investor flows are not available.

Oct 13, 20260 views